Intensive Aftercare Fails to Speed Lasting Return to Work for Employees with Mental Disorders

Mental disorders have become one of the leading causes of long-term sickness absence and disability across Europe, and their tendency to run a chronic or relapsing course makes a durable return to work notoriously difficult. In Germany, where employees transitioning from psychiatric treatment back into the workplace have historically had few structured supports, a large randomized controlled trial set out to test whether an intensified clinical aftercare program could change that picture. The results, published in BMC Psychiatry, are sobering for the intervention as a whole, yet they contain intriguing signals about which groups of employees might still stand to benefit.

The trial, led by Fiona Starke of the Federal Institute for Occupational Safety and Health in Berlin together with colleagues at Maastricht University and a network of German psychiatric clinics, evaluated a program called RTW-PIA, short for Return to work-Psychiatrische Institutsambulanz. The intervention was designed to fill a well-recognized gap: in Germany, aftercare programs aimed at maintaining recovery and minimizing relapse among employees moving from psychiatric outpatient treatment back to their jobs are scarce. RTW-PIA combined medical and psychotherapeutic care with work-oriented components over an eighteen-month period, making it a genuinely multimodal approach rather than a single-focus therapy.

To test the program rigorously, the researchers conducted a multicenter randomized controlled trial embedded in psychiatric outpatient clinics. They enrolled 484 employees who were on sick leave with a diagnosed mental disorder. Half of the participants, 240 in total, were randomly assigned to receive RTW-PIA in addition to usual care, while the remaining 244 received care as usual alone. Randomization of this kind ensures that differences in outcomes between the groups can be attributed to the intervention itself rather than to pre-existing differences in illness severity, motivation, or workplace circumstances.

The primary outcome was what the researchers call sustainable return to work, defined in a deliberately demanding way. A participant counted as achieving sustainable return to work only if, after fully returning to work, they accumulated no more than six weeks of additional sickness absence during the following twelve months. This definition matters because simply going back to work once is not the same as staying there; relapse and renewed absence are common among people with recurrent mental health conditions. Outcomes were measured at baseline and then at six, twelve, eighteen, and twenty-four months, giving the team a long observation window.

When the intention-to-treat analysis was complete, the headline finding was negative. Employees who received the intensified aftercare were not significantly more likely to achieve sustainable return to work than those receiving usual care. The odds ratio was 1.38 with a 95 percent confidence interval running from 0.89 to 2.12, an interval that crosses the threshold of statistical significance. In practical terms, the point estimate hinted at a possible advantage for the intervention group, but the data could not rule out that the true effect was absent or even slightly unfavorable.

The secondary outcomes told a similar story. The researchers examined measures such as return-to-work self-efficacy and work ability, and here again no significant differences emerged between the groups. What they did observe, however, was a consistent pattern of slight improvements favoring RTW-PIA across these measures. That consistency is worth noting: while none of the individual effects reached statistical significance, the direction of the results was uniform, which sometimes suggests that a real but modest effect may be diluted in an averaged analysis of a heterogeneous population.

The team took methodological rigor seriously. They complemented the primary intention-to-treat analysis with prespecified sensitivity analyses, including per-protocol and complete-case approaches, and these analyses led to the same conclusion as the main result. Latent growth curve models were used alongside logistic regression to track how outcomes changed over time, and missing data were handled under a missing-at-random assumption. The trial was also prospectively registered in the German Clinical Trials Register on September 1, 2021, before the first participant was enrolled, and ethical approval was obtained from the Ethics Committee at Hanover Medical School.

The most interesting findings emerged from the subgroup and moderator analyses. In diagnostic subgroup sensitivity analyses, employees with recurrent depressive disorders showed significant improvements in several secondary outcomes when they received the intensified aftercare. Prespecified exploratory moderator analyses suggested potential benefits for two further groups: employees without a recognized degree of disability, and those reporting low social support at work. After the researchers applied multiplicity adjustment to guard against false-positive findings, only recurrent depressive disorder still moderated the treatment effect, specifically on work ability. These patterns remain hypotheses rather than proven effects, and the authors are careful to state that they need to be tested in independent samples.

Why might an eighteen-month multimodal program fail to move the needle on sustainable return to work overall? The answer likely lies in the complexity of the problem itself. Returning to work after a mental disorder involves the interplay of clinical recovery, workplace conditions, social support, insurance and disability status, and individual circumstances that no single intervention can fully address. The moderator findings support this interpretation: employees who lacked workplace social support, who did not carry a formal disability designation, or who struggled with recurrent depression may represent subgroups where the added clinical and work-oriented components could genuinely tip the balance, while for others usual care may already suffice or other barriers may dominate.

The authors conclude that, on average, RTW-PIA did not significantly improve sustainable return to work or secondary outcomes, and they direct future research toward two priorities: testing the identified subgroup hypotheses in independent samples and studying how such an intervention could be implemented in practice. The trial was funded by the Innovation Fund of the Federal Joint Committee, Germany’s key health care decision-making body, between January 2021 and June 2025, with the funder having no role in the design, analysis, or interpretation. For a health system searching for ways to keep people with mental illness attached to the labor market, the study is a reminder that well-intentioned, resource-intensive aftercare is not automatically effective, but also that carefully designed subgroup research may yet reveal who benefits most and how support should be targeted.

Subject of Research: Effectiveness of intensified clinical aftercare for sustainable return to work among employees on sick leave with mental disorders

Article Title: Intensified return to work clinical aftercare for sick-listed employees with diagnosed mental disorders in Germany: effects of a multicentre randomized controlled trial

Article References: Starke, F., Zimmermann, J., Sikora, A., Houkes, I., Schulz, A., Stegmann, R., Seufert, L., Schmitz, E., Buntrock, C., Szycik, G. R., Borgolte, A., Unger, H.-P., Schumacher, J. O., Stark, H., Schneller, C., Unterschemmann, S.-L., de Rijk, A., & Wegewitz, U. (2026). Intensified return to work clinical aftercare for sick-listed employees with diagnosed mental disorders in Germany: effects of a multicentre randomized controlled trial. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08639-0

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08639-0

Keywords: return to work, mental disorders, aftercare, randomized controlled trial, sickness absence, recurrent depression, work ability, occupational health, psychiatric rehabilitation, Germany, sustainable employment, clinical trial